Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Clinical Oncology

• Publication date

  2011-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2011.35.0371PMID 21555683
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient‐specific NPM1 mutations

  2010influential reference
• Minimal residual disease diagnostics in patients with acute myeloid leukemia in the post-transplant period: comparison of peripheral blood and bone marrow analysis

  2010influential reference
• Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia.

  2010cited by this paper
• Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias.

  2010cited by this paper
• Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A.

  2010cited by this paper
• Harmonization of molecular monitoring of CML therapy in Europe

  2009cited by this paper
• Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy.

  2009cited by this paper
• Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: clonal evolution is a limiting factor

  2009cited by this paper
• Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.

  2009cited by this paper
• Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.

  2009cited by this paper
• Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

  2008cited by this paper
• Development of minimal residual disease-directed therapy in acute myeloid leukemia.

  2008cited by this paper
• Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features.

  2007cited by this paper
• Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention

  2007cited by this paper
• Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations

  2007cited by this paper
• Rapid and sensitive typing of NPM1 mutations using LNA-mediated PCR clamping

  2006cited by this paper
• Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia.

  2006cited by this paper
• Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations

  2006cited by this paper
• Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]

  2006cited by this paper
• Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.

  2005cited by this paper
• Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.

  2005influential reference
• Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.

  2005cited by this paper
• Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia.

  2005cited by this paper
• The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia.

  2005cited by this paper
• Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.

  2005cited by this paper
• A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.

  2004cited by this paper
• Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

  2003cited by this paper
• Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program

  2003cited by this paper
• Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis

  2001cited by this paper
• A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk

  1988cited by this paper
• Censoring distributions as a measure of follow-up in survival analysis.

  1986cited by this paper

• Biology and Management of Acute Myeloid Leukemia With Mutated NPM1

  2025cites this paper
• Prevalence of Classification of Nucleophosmin 1 Gene Mutations in Iraqi Cohort of Acute Myeloid Leukemia

  2025cites this paper
• Prognostic significance of deep sequencing for analysis of measurable residual disease in acute myeloid leukemia with NPM1 mutation

  2025cites this paper
• Intermediate-Dose Cytarabine as Postinduction AML Therapy.

  2025cites this paper
• Impact of Time to Treatment Initiation on Quality of Response in Patients with Acute Myeloid Leukemia Receiving Intensive Chemotherapy

  2025cites this paper
• Next-Generation Sequencing for Minimal Residual Disease Detection in AML: Current Technologies and Clinical Implications.

  2025influential citation
• A pooled analysis of 3 large multicenter trials confirms a survival advantage for NPM1 mut AML in MRDneg remission after intensive induction

  2025cites this paper
• Measurable residual disease monitoring in acute myeloid leukaemia: Techniques, timing and therapeutic implications.

  2025cites this paper
• Flow cytometric and molecular MRD in AML: current methods, clinical applications and challenges

  2025cites this paper
• Validation Study of Analytical Methods for Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia

  2025influential citation
• Minimal Residual Disease Detection: Implications for Clinical Diagnosis and Cancer Patient Treatment

  2025cites this paper
• Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trials.

  2025cites this paper
• Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML

  2025cites this paper
• Measurable residual disease‐guided therapy in acute myeloid leukaemia: Practical insights

  2025cites this paper
• Phase 1 study of chidamide in combination with venetoclax, azacitidine, aclarubicin, cytarabine and G-CSF for refractory/relapsed acute myeloid leukemia: clinical safety, efficacy, and correlative analysis

  2025cites this paper
• Acute Myeloid Leukemia-Use of Measurable Residual Disease to Improve Outcomes.

  2025cites this paper
• Validation of a Multiplex mRNA- and gDNA-Based Droplet Digital PCR Assay in Acute Myeloid Leukemia Patients with an NPM1 Mutation.

  2025cites this paper
• Pre-emptive therapeutic decisions based on measurable residual disease status in acute myeloid leukemia: ready for prime time?

  2024cites this paper
• Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia

  2024influential citation
• Recent advances in AML with mutated NPM1

  2024cites this paper
• Low Dimensional Representation of Multi‐Patient Flow Cytometry Datasets Using Optimal Transport for Measurable Residual Disease Detection in Leukemia

  2024cites this paper
• Measurable residual disease monitoring in AML: Prospects for therapeutic decision‐making and new drug development

  2024influential citation
• Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient.

  2024cites this paper
• Relationship between donor source, pre-transplant measurable residual disease, and outcome after allografting for adults with acute myeloid leukemia

  2024cites this paper
• Advantages of a genomic DNA-based next-generation sequencing assay for detection of mutant NPM1 measurable residual disease in AML

  2024cites this paper
• Acute myeloid leukemia management and research in 2025

  2024cites this paper
• Molecular Features and Treatment Paradigms of Acute Myeloid Leukemia

  2024cites this paper
• Post induction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.

  2024cites this paper
• SOHO State of the Art Updates and Next Questions: Pre-emptive Therapy at Molecular Measurable Residual Disease Failure in Acute Myeloid Leukemia.

  2024cites this paper
• Current status and research directions in acute myeloid leukemia

  2024cites this paper
• Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia – a FILO study

  2024cites this paper
• Detection methods and prognosis implications of measurable residual disease in acute myeloid leukemia

  2024cites this paper
• Is Favorable-Risk AML Always Favorable?

  2024cites this paper
• Quantifying NPM1 MRD in AML patients prior to allogeneic stem cell transplantation: Where to draw the line?

  2024cites this paper
• Prognostic impact of measurable residual clonal hematopoiesis in acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation

  2023cites this paper
• Criteria for diagnosis and molecular monitoring of NPM1-mutated AML.

  2023cites this paper
• Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease

  2023cites this paper
• Allogeneic hematopoietic stem cell transplantation and pre-transplant strategies in patients with NPM1- mutated acute myeloid leukemia

  2023cites this paper
• Fludarabine, cytarabine, and idarubicin with or without venetoclax in patients with relapsed/refractory acute myeloid leukemia

  2023influential citation
• How I treat refractory and relapsed acute myeloid leukemia.

  2023cites this paper
• Experimental drugs in clinical trials for acute myeloid leukemia: innovations, trends, and opportunities

  2023cites this paper
• A venetoclax and azacitidine bridge‐to‐transplant strategy for NPM1‐mutated acute myeloid leukaemia in molecular failure

  2023cites this paper
• Challenges of detecting measurable/minimal disease in acute leukemia.

  2023cites this paper
• Molecular MRD Assessment in Acute Myeloid Leukemias

  2023cites this paper
• Current and Emerging Techniques for Diagnosis and MRD Detection in AML: A Comprehensive Narrative Review

  2023cites this paper
• Venetoclax–based low intensity therapy in molecular failure of NPM1-mutated AML

  2023cites this paper
• Allogeneic hematopoietic stem cell transplantation and pre-transplant strategies in patients with NPM1-mutated acute myeloid leukemia: a single center experience

  2023cites this paper
• NPM1‐mutated acute myeloid leukemia: New pathogenetic and therapeutic insights and open questions

  2023cites this paper
• Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based non-intensive therapy.

  2023cites this paper
• Clinical Implications of the FLT3-ITD Allelic Ratio in Acute Myeloid Leukemia in the Context of an Allogeneic Stem Cell Transplantation

  2023cites this paper
• The clinical impact of the molecular landscape of acute myeloid leukemia

  2023cites this paper
• Assessment of acute myeloid leukemia molecular measurable residual disease testing in an interlaboratory study

  2023cites this paper
• Midostaurin therapy for indolent and smoldering systemic mastocytosis: Retrospective review of Mayo Clinic experience

  2022cites this paper
• Applying molecular measurable residual disease testing in acute myeloid leukaemia.

  2022cites this paper
• Measurable Residual Disease Monitoring by Locked Nucleic Acid Quantitative Real-Time PCR Assay for IDH1/2 Mutation in Adult AML

  2022cites this paper
• Monitoring Minimal Residual Disease in RUNX1-Mutated Acute Myeloid Leukemia

  2022cites this paper
• Wilms tumor 1 gene expression in acute myeloid leukemia: prognostic significance and usefulness in minimal residual disease monitoring—a case–control study

  2022cites this paper
• Acute myeloid leukemia: therapeutic targeting of stem cells

  2022cites this paper
• A dynamic 3‐factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy

  2022cites this paper
• Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia

  2022cites this paper
• Panel Analysis: Hematological Malignancies

  2022cites this paper
• Prognostic impact of early minimal residual disease combined with complete molecular evaluation in acute myeloid leukemia with mutated NPM1: a single center study

  2022cites this paper
• Standards der kurativen Systemtherapie der akuten myeloischen Leukämie

  2022cites this paper
• Acute myeloid leukemia displaying clonal instability during treatment: implications for measurable residual disease assessments.

  2022cites this paper
• The Role of Nucleophosmin 1 (NPM1) Mutation in the Diagnosis and Management of Myeloid Neoplasms

  2022cites this paper
• Sequential next generation sequencing analysis in homogeneously treated low risk NPM1‐mutated acute myeloid leukemia with an adverse clinical outcome

  2022cites this paper
• Allogene Stammzelltransplantation bei akuten Leukämien

  2022cites this paper
• Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis

  2022cites this paper
• Nucleophosmin 1: from its pathogenic role to a tantalizing therapeutic target in acute myeloid leukemia

  2022cites this paper
• NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemia

  2022cites this paper
• The Prognostic Value of Early Detection of Minimal Residual Disease as Defined by Flow Cytometry and Gene Mutation Clearance for Myelodysplastic Syndrome Patients After Myeloablative Allogeneic Hematopoietic Stem-Cell Transplantation

  2021cites this paper
• Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia

  2021cites this paper
• Treatment of Newly Diagnosed AML in Fit Patients

  2021cites this paper
• Post-Induction Treatment for Acute Myeloid Leukemia: Something Change?

  2021cites this paper
• Role of Minimal Residual Disease Testing in Acute Myeloid Leukemia.

  2021cites this paper
• Neoantigen-Specific T-Cell Immune Responses: The Paradigm of NPM1-Mutated Acute Myeloid Leukemia

  2021cites this paper
• Combined use of interferon alpha-1b, interleukin-2, and thalidomide to reverse the AML1-ETO fusion gene in acute myeloid leukemia

  2021cites this paper
• Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML.

  2021cites this paper
• Treatment for Relapsed/Refractory Acute Myeloid Leukemia

  2021cites this paper
• The Impact of DNMT3A Status on NPM1 MRD Predictive Value and Survival in Elderly AML Patients Treated Intensively

  2021cites this paper
• Nucleophosmin1 and isocitrate dehydrogenase 1 and 2 as measurable residual disease markers in acute myeloid leukemia

  2021cites this paper
• Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field

  2021cites this paper
• Measurable residual disease (MRD) monitoring by next-generation sequencing before allogeneic hematopoietic cell transplantation in AML

  2021cites this paper
• Descriptive and Functional Genomics in Acute Myeloid Leukemia (AML): Paving the Road for a Cure

  2021cites this paper
• Acute myeloid leukemia: current progress and future directions

  2021cites this paper
• Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach

  2021cites this paper
• Peripheral blood molecular measurable residual disease is sufficient to identify patients with acute myeloid leukaemia with imminent clinical relapse

  2021influential citation
• Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades.

  2021cites this paper
• Precision medicine in myeloid malignancies.

  2021cites this paper
• The Impact of DNMT3A Status on NPM1 MRD Predictive Value and Survival in Elderly AML Patients Treated Intensively.

  2021cites this paper
• Optimizing Transplant Approaches and Post-Transplant Strategies for Patients With Acute Myeloid Leukemia

  2021cites this paper
• Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin.

  2021cites this paper
• Molecular methods for measurable residual disease in acute myeloid leukemia: where are we and where are we going?

  2021cites this paper
• Comparison of RNA‐ and DNA‐based methods for measurable residual disease analysis in NPM1‐mutated acute myeloid leukemia

  2021cites this paper
• CD9, a potential leukemia stem cell marker, regulates drug resistance and leukemia development in acute myeloid leukemia

  2021cites this paper
• 急性髓系白血病微小残留病检测与临床解读中国专家共识（2021年版）

  2021cites this paper
• Genomic Landscape and Clonal Evolution of AML

  2021cites this paper
• Clinical values of gene alterations as marker of minimal residual disease in non-M3 acute myeloid leukemia

  2021cites this paper
• Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia

  2021cites this paper
• NPM1+ /FLT3- Acute Myeloid Leukemia after JAK2-V617F+ Essential Thrombocythemia. Management and Prognosis

  2021cites this paper